BioCatalyst

Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Riluzole (100 mg) — catalyst calendar

1 verified catalyst event(s) referencing Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Riluzole (100 mg), each linked to its official source. Verified as of 2026-11-02.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
Phase 2 · Amyotrophic Lateral Sclerosis (ALS)
 PhenoNet, Inc. Cromolyn Sodium (34.2 mg BID), Cromolyn ClinicalTrials.gov ↗
✓ Source-checked 2026-11-02
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.